Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: evidence for the involvement of inflammation and angiogenesis/angiostasis in this disease state

Clin Lab. 2013;59(1-2):133-7. doi: 10.7754/clin.lab.2012.120225.

Abstract

Background: Recent evidence has demonstrated that environment and genetic factors play pivotal roles in diabetes and its related complications. The significant contributory role of cytokines in pathogenesis of type 2 diabetes is also well documented. This study was aimed to examine and compare both CXCL1 (GRO-alpha) and CXCL10 (IP-10) circulating levels in type 2 diabetic patients and healthy controls.

Methods: Peripheral blood samples were collected from 100 type 2 diabetic patients and 150 healthy controls. Circulating CXCL1 and CXCL10 levels were measured by ELISA.

Results: Elevated serum levels of both CXCL1 and CXCL10 were found in type 2 diabetic patients in comparison to controls.

Conclusions: Elevated levels of CXCL1 and CXCL10 could possibly be used as a marker of inflammation and angiogenesis/angiostasis in type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood*
  • Case-Control Studies
  • Chemokine CXCL1 / blood*
  • Chemokine CXCL10 / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Inflammation / blood*
  • Male
  • Middle Aged
  • Neovascularization, Pathologic*

Substances

  • Biomarkers
  • CXCL10 protein, human
  • Chemokine CXCL1
  • Chemokine CXCL10